Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/143718
Title: ADAM10 in Alzheimer's disease: Pharmacological modulation by natural compounds and its role as a peripheral marker
Author: Manzine, Patricia
Ettcheto Arriola, Miren
Cano Fernández, Amanda
Busquets Figueras, Oriol
Marcello, Elena
Pelucchi, Silvia
Di Luca, Monica
Endres, Kristina
Olloquequi González, Jordi
Camins Espuny, Antoni
Cominetti, Márcia Regina
Keywords: Malaltia d'Alzheimer
Proteïnes
Farmacologia
Alzheimer's disease
Proteins
Pharmacology
Issue Date: 3-Apr-2019
Publisher: Elsevier Masson SAS
Abstract: Alzheimer's disease (AD) represents a global burden in the economics of healthcare systems. Amyloid-β (Aβ) peptides are formed by amyloid-β precursor protein (AβPP) cleavage, which can be processed by two pathways. The cleavage by the α-secretase A Disintegrin And Metalloprotease 10 (ADAM10) releases the soluble portion (sAβPPα) and prevents senile plaques. This pathway remains largely unknown and ignored, mainly regarding pharmacological approaches that may act via different signaling cascades and thus stimulate non-amyloidogenic cleavage through ADAM10. This review emphasizes the effects of natural compounds on ADAM10 modulation, which eventuates in a neuroprotective mechanism. Moreover, ADAM10 as an AD biomarker is revised. New treatments and preventive interventions targeting ADAM10 regulation for AD are necessary, considering the wide variety of ADAM10 substrates.
Note: Versió postprint del document publicat a: https://doi.org/10.1016/j.biopha.2019.108661
It is part of: Biomedicine & Pharmacotherapy, 2019
URI: http://hdl.handle.net/2445/143718
Related resource: https://doi.org/10.1016/j.biopha.2019.108661
ISSN: 0753-3322
Appears in Collections:Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)

Files in This Item:
File Description SizeFormat 
691035.pdf797.45 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.